Drug Trial Radar · NCT07107204
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Jan 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Biotroy TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years . Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.
Conditions
- Relapsed or Refractory Hematologic Malignancies
- Leukemia
- Lymphoma
- Multiple Myeloma (MM)
Interventions
BT02Drug
BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Through the study completion, an average of 2.5 years
- Dose limited toxicity(DLT)Time frame: Through the dose escalation phase, an average of 10 months
- Maximum tolerable dose(MTD)Time frame: Through the dose escalation phase, an average of 10 months
- Recommended phase 2 dose(RP2D)Time frame: Through the study completion, an average of 2.5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.